The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer

Breast

Volumn 23, Issue 3, 2014, Pages 201-208

  Ciruelos, Eva ^a   Pascual, Tomás ^a   Arroyo Vozmediano, María Luisa ^a   Blanco, Marta ^a   Manso, Luis ^a   Parrilla, Lucía ^a   Muñoz, Cesar ^a   Vega, Estela ^a   Calderón, Monica Jackelin ^a   Sancho, Blanca ^a   Cortes Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Aromatase inhibitor; Endocrine treatment; Fulvestrant; Hormone receptor positive breast cancer; Selective estrogen receptor down regulators; Selective estrogen receptor modulators

Indexed keywords

ANASTROZOLE; APITOLISIB; BEVACIZUMAB; BUPARLISIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; GOSERELIN; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PLACEBO; TAMOXIFEN; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONIST; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ASTHENIA; BONE PAIN; BREAST CANCER; BRONCHITIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONSTIPATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; GROWTH INHIBITION; HEADACHE; HOT FLUSH; HUMAN; MYALGIA; NAUSEA; OSTEOARTHRITIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DOSE RESPONSE; FEMALE; METABOLISM; OUTCOME ASSESSMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84899894839     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.01.016     Document Type: Review

References (51)

1. Jatoi I., Chen B.E., Anderson W.F., Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007, 25:1683-1690.
2. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995, 13:513-529.
3. EMA. Faslodex. Product Information.
4. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991, 51:3867-3873.
5. Ingle J.N., Suman V.J., Rowland K.M., Mirchandani D., Bernath A.M., Camoriano J.K., et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006, 24:1052-1056.
6. Perey L., Paridaens R., Hawle H., Zaman K., Nole F., Wildiers H., et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007, 18:64-69.
7. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26:1664-1670.
8. Hyder S.M., Chiappetta C., Murthy L., Stancel G.M. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 1997, 57:2547-2549.
9. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993, 106(Pt 4):1377-1388.
10. Parker M.G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993, 26:131-137.
11. Pink J.J., Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996, 56:2321-2330.
12. Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000, 7:17-28.
13. Robertson J.F., Nicholson R.I., Bundred N.J., Anderson E., Rayter Z., Dowsett M., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001, 61:6739-6746.
14. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000, 89:817-825.
15. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
16. DeFriend D.J., Anderson E., Bell J., Wilks D.P., West C.M., Mansel R.E., et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994, 70:204-211.
17. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87:746-750.
18. DeFriend D.J., Howell A., Nicholson R.I., Anderson E., Dowsett M., Mansel R.E., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994, 54:408-414.
19. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, 345:29-30.
20. Howell A., DeFriend D.J., Robertson J.F., Blamey R.W., Anderson L., Anderson E., et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996, 74:300-308.
21. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
22. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
23. Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
24. Buzdar A.U., Jonat W., Howell A., Jones S.E., Blomqvist C.P., Vogel C.L., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
25. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810.
26. Robertson J.F., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
27. Howell A., Pippen J., Elledge R.M., Mauriac L., Vergote I., Jones S.E., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005, 104:236-239.
28. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
29. Fallowfield L., Atkins L., Catt S., Cox A., Coxon C., Langridge C., et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17:205-210.
30. Jelovac D., Macedo L., Goloubeva O.G., Handratta V., Brodie A.M. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005, 65:5439-5444.
31. Macedo L.F., Sabnis G.J., Goloubeva O.G., Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008, 68:3516-3522.
32. Bergh J., Jonsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattstrom D., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30:1919-1925.
33. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444.
34. Patterson J.S., Settatree R.S., Adam H.K., Kemp J.V. Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response. Eur J Cancer 1980, 1:89-92. Suppl.
35. Kuter I., Gee J.M., Hegg R., Singer C.F., Badwe R.A., Lowe E.S., et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 2012, 133:237-246.
36. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
37. Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27:4530-4535.
38. Robertson J.F., Lindemann J.P., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012, 136:503-511.
39. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., et al. Final analysis of overall survival for the phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. San Antonio Breast Cancer Symposium 2012, S1-S4. Abstract.
40. Martin M., Loibl S., von Minckwitz G., Morales S., Crespo C., Anton A., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - first efficacy results from the LEA study. Cancer Research 2012, 72.
41. Tokunaga E., Kataoka A., Kimura Y., Oki E., Mashino K., Nishida K., et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 2006, 42:629-635.
42. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
43. Jelovac D., Sabnis G., Long B.J., Macedo L., Goloubeva O.G., Brodie A.M. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 2005, 65:5380-5389.
44. Beeram M., Tan Q.T., Tekmal R.R., Russell D., Middleton A., DeGraffenried L.A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328.
45. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637.
46. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
47. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30:2718-2724.
48. Juric D., Rodon J., González-Angulo A.M., Burris H.A., Bendell J., Berlin J.D., et al. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res. 2012, 72(Suppl 8). Abstract CT-01.
49. Steger G., Bartsch R., Wenzel C., Hussian D., Sevelda U., Pluschnig U., et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: a pilot study. ASCO Meeting Abstracts 2005, 23. Abstract 708.
50. Chlebowski R.T., Geller M.L. Adherence to endocrine therapy for breast cancer. Oncology 2006, 71:1-9.
51. Hershman D.L., Kushi L.H., Shao T., Buono D., Kershenbaum A., Tsai W.Y., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28:4120-4128.